Entries by IPOPI

Safety and Efficacy of Immunoglobulin: A Guide for Users, Assessors and Funders

This  IPOPI publication is available for download on our website. Within a national healthcare system, selection of immunoglobulin (IG) therapies for conditions such as Primary Immunodeficiencies (PIDs) is difficult. In well-resourced countries, regulatory agencies make key decisions regarding such therapies’ quality and safety; such regulatory agencies, including the U.S. Food and Drug Administration (FDA) and […]

European Reference Network for PIDs a key element for improving PID care in Europe

Participants to the IPOPI 2016 World Primary Immunodeficiency Week Policy event identified European Reference Networks as an essential tool to improve care for PID patients. IPOPI is currently collaborating in the development of the Rare Immunodeficiency, AuToinflammatory and Autoimmune (RITA) Network, a European Reference Network uniting under the same umbrella, specialised centres in Europe dedicated […]